Yifan Pharmaceutical: Announcement on the extension of pledge of shares by the controlling shareholder
Yifan Pharmaceutical: Announcement regarding obtaining pharmaceutical registration certificate.
Yifan Pharmaceutical: Announcement on the receipt of a notice of acceptance of drug registration by a wholly-owned subsidiary
Yifan Pharmaceutical: Announcement on progress in providing guarantees to wholly-owned subsidiaries
Yifan Pharmaceutical: Announcement of Resolutions of the 2023 Annual General Meeting of Shareholders
Yifan Pharmaceutical: Legal Opinion of Anhui Tianhe Law Firm on the 2023 Annual General Meeting of Shareholders of Yifan Pharmaceutical Co., Ltd.
Yifan Pharmaceutical: Announcement on Ginkgo Biloba Pills Obtaining Registration Approval in Singapore
Yifan Pharmaceutical: 002019 Yifan Pharmaceutical Investor Relations Management Information 20240507
Yifan Pharmaceutical: Announcement on the proposed selection of wholly-owned subsidiaries to participate in the national centralized drug procurement (insulin special continuation)
Yifan Pharmaceutical: Announcement on Obtaining a Notice of Approval of the Drug Supplement Application
Yifan Pharmaceutical: Announcement on Obtaining a Drug Registration Certificate
Yifan Pharmaceutical: Report for the first quarter of 2024
Yifan Pharmaceutical: Announcement on changing the disclosure time of the report for the first quarter of 2024
Yifan Pharmaceutical: Nomination Committee Rules of Procedure (Revised in April 2024)
Yifan Pharmaceutical: Report on the Audit Committee's performance of supervisory duties on accounting firms in 2023
Yifan Pharmaceutical: 2023 Supervisory Committee Work Report
Yifan Pharmaceutical: Remuneration and Assessment Committee Rules of Procedure (revised in April 2024)
Yifan Pharmaceutical: Special Instructions of the Board of Directors on Accounting Policy Changes and Retroactive Adjustment of Financial Statement Data
Yifan Pharmaceutical: Announcement on the Use of Own Funds for Outsourced Financial Management
Yifan Pharmaceutical: Announcement on preparations for asset impairment in 2023
No Data